(a)The following individuals are at increased risk of COVID-19 disease and should receive COVID-19 vaccine dose(s) as soon as it becomes available in the fall AND should receive an additional dose in the spring:
- Individuals aged 80 years and older
- Residents in long-term care homes aged 18 years and older
- Residents in congregate living settings aged 65 years and older
- Adults aged 65 to 79 years with any of the following underlying medical conditions:
- Cancer
- Cerebrovascular disease
- Chronic kidney disease
- Chronic liver diseases (limited to cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, and autoimmune hepatitis)
- Chronic lung diseases (limited to bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary hypertension, pulmonary embolism)
- Cystic fibrosis
- Diabetes mellitus, type 1 and type 2
- Disabilities (e.g. Down syndrome, learning, intellectual, or developmental disabilities; ADHD; cerebral palsy; congenital disabilities; spinal cord injuries)
- Heart conditions (e.g., cardiomyopathies, coronary artery disease, heart failure, etc.)
- HIV infection
- Mental health disorders (limited to mood disorders, including depression; schizophrenia spectrum disorders)
- Obesity
- Pregnancy and recent pregnancy
- Primary immunodeficiency diseases
- Smoking, current or former
- Solid organ or blood stem cell transplant
- Tuberculosis
- Use of corticosteroids or other immunosuppressive medication
- Individuals aged 6 months and older who are moderately to severely immunocompromised who meet any of the following criteria:
-
- solid tumour or hematologic malignancies or treatments for these conditions
- solid-organ transplant and taking immunosuppressive therapy
- hematopoietic stem cell transplant (HSCT) (within 2 years of transplantation or taking immunosuppression therapy). See re-vaccination information.
- immunocompromised due to chimeric antigen receptor (CAR) T cell therapy targeting lymphocytes. See re-vaccination information.
- moderate to severe primary immunodeficiency with associated humoral and/or cell-mediated immunodeficiency or immune dysregulation
- HIV with AIDS-defining illness or TB diagnosis in last 12 months before starting vaccine series, or severe immune compromise with CD4 ‹ 200 cells/μL or CD4<15%, or without HIV viral suppression
- recent treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive
- chronic kidney disease on dialysis
- Individuals aged 55 years and older who identify as First Nations, Inuit, or Metis and their non-Indigenous household members aged 55 years and older.
(b) The following individuals are at increased risk of COVID-19 disease and should receive COVID-19 vaccine dose(s) as soon as it becomes available in the fall AND may receive an additional dose in the spring:
Individuals aged 65 to 79 years (not on the list above).